The 36-month beta value for DNTH is at 1.38. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DNTH is 22.32M, and currently, shorts hold a 28.71% of that float. The average trading volume for DNTH on June 13, 2025 was 350.37K shares.
DNTH) stock’s latest price update
Dianthus Therapeutics Inc (NASDAQ: DNTH) has experienced a rise in its stock price by 6.46 compared to its previous closing price of 18.12. However, the company has seen a gain of 3.88% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company’s participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors.
DNTH’s Market Performance
Dianthus Therapeutics Inc (DNTH) has experienced a 3.88% rise in stock performance for the past week, with a 2.39% rise in the past month, and a -9.35% drop in the past quarter. The volatility ratio for the week is 4.88%, and the volatility levels for the past 30 days are at 2.77% for DNTH. The simple moving average for the past 20 days is 4.82% for DNTH’s stock, with a -16.61% simple moving average for the past 200 days.
Analysts’ Opinion of DNTH
Oppenheimer, on the other hand, stated in their research note that they expect to see DNTH reach a price target of $48. The rating they have provided for DNTH stocks is “Outperform” according to the report published on October 03rd, 2024.
Robert W. Baird gave a rating of “Outperform” to DNTH, setting the target price at $58 in the report published on July 26th of the previous year.
DNTH Trading at 1.51% from the 50-Day Moving Average
After a stumble in the market that brought DNTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.22% of loss for the given period.
Stock Fundamentals for DNTH
Current profitability levels for the company are sitting at:
- -17.96 for the present operating margin
- 1.0 for the gross margin
The net margin for Dianthus Therapeutics Inc stands at -15.44. The total capital return value is set at -0.35. Equity return is now at value -28.73, with -27.56 for asset returns.
Based on Dianthus Therapeutics Inc (DNTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -56.01.
Currently, EBITDA for the company is -101.45 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 93.75. The receivables turnover for the company is 6.52for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.99.
Conclusion
In conclusion, Dianthus Therapeutics Inc (DNTH) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
